Microba Launches Next Generation Healthcare Testing
28.2.2023 12:44:00 EET | Business Wire | Press release
Microba Life Sciences Limited (ASX: MAP) (“Microba”), a precision microbiome company, is pleased to announce that it’s next generation testing product range, MetaXplore™ has been launched to healthcare professionals in Australia under a new brand, Co-Biome™. This delivers on the new healthcare product launch milestone prefaced in the FY22 Annual Report and updated in quarterly reports following the closed beta release in June 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005713/en/
MetaXplore™ GI Plus can help you explore the impact your patients’ gut microbiome may be having on their health. MetaXplore™ GI Plus translates diagnostic gastrointestinal markers and targeted pathogen, protist and parasite panels1 alongside metagenomic-driven gut microbiome insights2 for over 28,000* microbial species and their function. (Photo: Business Wire)
Microba’s Chief Executive Officer, Dr Luke Reid said, “The new MetaXplore™ test range delivers an important advancement in how microbiome test information can be applied in a healthcare setting. We continue to make progress at the forefront of this field to advance the application of microbiome testing in a healthcare setting towards a future where it can be routine in health and disease management, much like a blood test is today.”
The new MetaXplore™ range provides diagnostic gastrointestinal health testing together with metagenomic-driven gut microbiome analysis to deliver comprehensive gastrointestinal testing solutions for Healthcare Professionals. The MetaXplore™ test range has been developed together with healthcare professionals and brought to market under a new brand called Co-Biome™.
The range consists of 3 products: MetaXplore™, MetaXplore™ GI and MetaXplore™ GI Plus. Key features include:
- Easy to interpret report format designed specifically for healthcare professionals to support efficient patient consultation
- Scientifically graded clinical insights using National Health and Medical Research Council guidelines
- Diagnostic and investigative gastrointestinal health markers (faecal calprotectin, faecal occult blood, lactoferrin, pancreatic elastase, secretory IgA, Zonulin, Fecal pH)
- Diagnostic pathogen and parasite detection (E.coli pathotypes, C.difficile pathotypes, Campylobacter spp., Yersinia enterocolitica, Vibrio spp., Aeromonas spp., Salmonella spp., Giardia lamblia, Entamoeba histolytica, Cryptosporidium spp., Dientamoeba fragilis, Cyclospora cayetanensis.)
- Complete microbiome profiling (Microbial diversity, richness and profiling of over 28,000+ microbial species including bacteria, fungi, parasite and archaea detection, together with parasite detection of Blastocystis subtypes 1-9 and other eukaryotes)
- Microbiome production and consumption of metabolites (Butyrate, acetate, propionate, 3-indolepropionic acid (IPA), hexa-acylated, lipopolysaccharides (hexa-LPS), trimethylamine (TMA), hydrogen sulphide, branched-chain amino acids (BCAA), B.fragilis toxin, methane, beta-glucuronidase, Mucin, oxalate)
A core component of Microba’s strategy is to leverage the Company’s world-leading technology and capability to advance the clinical application of microbiome testing to become embedded as a routine part of health and disease management. The MetaXplore™ test range through Co-Biome™ represents an important step forward in that strategy by breaking new ground in the application of microbiome testing in healthcare.
Microba’s Chief Scientific Officer, Assoc Prof. Lutz Krause said, “These new tests integrate traditional gastrointestinal pathology tools with Microba’s next generation microbiome testing technology and the latest global research to significantly advance the utility of microbiome testing in a healthcare setting. This test range is expected to significantly expand the total addressable market for Microba’s testing products.”
The test range through Co-Biome™ can be accessed in Australia through a healthcare professional, and following the launch, it is expected to then be rolled out through Microba’s growing international distribution partner network.
About Microba Life Sciences Limited
Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005713/en/
Contact information
Simon Hinsley simon@nwrcommunications.com.au
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HTEC and Xsolis’ Strategic Partnership to Tackle Inefficiencies in Healthcare Decision-Making with AI2.6.2026 15:38:00 EEST | Press release
HTEC, the global AI-first engineering and digital product development company, today announced a strategic partnership with Xsolis, an AI-driven technology company that reduces administrative waste by enabling collaboration between healthcare providers and payers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602462348/en/ HTEC, the global AI-first engineering and digital product development company, today announced a strategic partnership with Xsolis, an AI-driven technology company that reduces administrative waste by enabling collaboration between healthcare providers and payers. Across healthcare systems, determining whether a treatment is medically necessary, what level of care a patient requires, and whether that care will be approved remains a slow, manual, and often inconsistent process. Known as utilization management, this function sits at the heart of healthcare operations—but is still heavily reliant on fragm
Perpetuals Reports $ 4.5 Billion in UpsideOnly Volume and Signs Exchange Agreement With Datavault AI for Tokenized Commodities2.6.2026 15:00:00 EEST | Press release
Perpetuals.com Ltd (Nasdaq: PDC) today reported strong early results for its breakout UpsideOnly trading and market prediction platform and announced an agreement with Datavault AI Inc. (Nasdaq: DVLT) to list tokenized real-world commodity assets on the Perpetuals platform. In its first two weeks, traders flocked to the UpsideOnly platform, attracting more than 30,000 active users, generating $4.5 billion in cumulative platform volume across 186,000 fills and 25 instruments. Reflecting the widespread demand for a risk-free product, users came from 185 different countries. Surprisingly, gold was the top instrument with $1.4 billion in volume, outpacing bitcoin at $1.2 billion with precious metals accounting for roughly 35 percent of total platform activity. UpsideOnly is the first trading and market prediction platform where users can't lose. Traders make predictions across global markets and share in profits when those predictions are validated by Perpetuals's proprietary AI, without e
Phenom Positioned as Strategic Leader in Fosway 9-Grid™ for Talent Acquisition Sixth Consecutive Year2.6.2026 15:00:00 EEST | Press release
Phenom, the leader in applied AI with an infrastructure built specifically to redesign work operations, has been positioned as a Strategic Leader in the 2026 Fosway 9-Grid™ for Talent Acquisition for the sixth year in a row. The positioning reinforces Phenom’s focus on sustained execution and customer impact at a moment when most enterprises remain stuck between AI ambition and AI that works. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602897994/en/ Phenom has been positioned as a Strategic Leader in the 2026 Fosway 9-Grid™ for Talent Acquisition for the sixth year in a row. The positioning reinforces Phenom’s focus on sustained execution and customer impact at a moment when most enterprises remain stuck between AI ambition and AI that works. The execution gap is well documented. Fosway’s recent AI Market Assessment for Talent Acquisition found that only 27% of AI features claimed by talent acquisition vendors are actu
How Fit Analytics Innovation Reclaimed its Independence to Build the Future of AI Commerce2.6.2026 14:47:00 EEST | Press release
With today’s launch of the AI Shopping Assistant, Fit Analytics Innovation moves beyond the AI-hype-cycle to deliver the conversational guidance modern apparel shoppers crave. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602315868/en/ AI Shopping Assistant - Fit Analytics Innovation Two years ago, Fit Analytics Innovation did the unthinkable: they bought themselves back. Following a high-profile acquisition by Snap Inc., the management team recovered the award-winning Fit Finder and secured sixteen years of expertise and data insights. That bet on independence has culminated in the launch of the AI Shopping Assistant, the latest module available as part of their expanded product suite. Delivering Performance Over P.R. Unlike "overnight" AI startups rushing for market share, Fit Analytics has utilized its independence to prioritize depth over hype. The resulting AI Shopping Assistant is a native evolution of the company’
Kinaxis Introduces Forward Deployed Engineering to Help Enterprises Turn Decisions into Outcomes2.6.2026 14:01:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain planning and orchestration, today introduced Forward Deployed Engineering (FDE), a new engagement model designed to help enterprises operationalize AI and translate decisions into measurable business outcomes. FDE reflects the broader Kinaxis vision for operational orchestration, an approach that coordinates signals, decisions, actions and learnings across the business fast enough to change outcomes. The opening keynote at Kinexions, the company’s global customer conference, delivered by CEO Razat Gaurav will be livestreamed globally on June 2 @ 11:30 am EST via LinkedIn Live. This approach combines a unified data foundation with semantic intelligence that understands the relationships, dependencies, and trade-offs that shape enterprise operations. Together, these capabilities help organizations move beyond isolated decision-making to coordinated execution, connecting data, systems, teams, and actions across the enterprise. Tradi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom